News & Blog

Nickel JC, Mills IW, Crook TJ, Jorga A, Smith MD, Atkinson G, Krieger JN. Tanezumab Reduces Pain in Women with Interstitial Cystitis/Bladder Pain Syndrome and Patients with Non-Urological Associated Somatic Syndromes. J Urol. 2015 Nov 11. pii: S0022-5347(15)05216-7. doi: 10.1016/j.juro.2015.10.178. [Epub ahead of print]

Previously, a monoclonal antibody treatment called tanezumab has been evaluated in several small clinical trials of patients with chronic pelvic pain. Now, to identify which patients are most likely to benefit from tanezumab, investigators have pooled data from different trials and analyzed the data in aggregate. The trials included a total of 208 patients with interstitial cystitis/bladder pain syndrome (IC/BPS) or chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The average decrease in pain symptoms was significant for women with IC/BPS, but not for men with CP/CPPS. Moreover, the decrease in pain intensity was significant for patients who had symptoms suggestive of some other associated non-urological pain syndromes, but not for patients who only had pelvic pain symptoms. Taken together, these findings suggest that the women most likely to benefit from tanezumab treatment would be those with IC/BPS plus a non-urological syndrome.